SKIN CANCERS

The anti-PD-1 therapy nivolumab demonstrated an overall objective response rate of 31%, with a median duration of 2 years in patients with advanced melanoma.

Combination therapy with ipilimumab and nivolumab led to durable tumor shrinkage in approximately half of patients with aggressive, advanced melanoma.

Antoni Ribas, MD, PhD, comments on the efficacy of lambrolizumab, an anti-PD-1 antibody, in patients with advanced melanoma.

Clifford A. Hudis, MD, Attending Physician, Memorial Sloan-Kettering Cancer Center, discusses his optimism surrounding immunotherapy for cancer care.

Richard D. Carvajal, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, describes the use of selumetinib in patients with advanced uveal melanoma.

Lynn M. Schuchter, MD, Chief, Hematology Oncology, Department of Medicine, University of Pennsylvania, gives an overview of the treatment of advanced melanoma at the 2013 ASCO Annual Meeting.

The FDA approved both dabrafenib (Tafinlar) and trametinib (Mekinist) for the treatment of patients with metastatic or unresectable melanoma.